Early venous thromboembolism at the beginning of palliative chemotherapy is a poor prognostic factor in patients with metastatic pancreatic cancer: A retrospective study

Jung Sun Kim, Eun Joo Kang, Dae Sik Kim, Yoon Ji Choi, Suk Young Lee, Hong Jun Kim, Hee Yeon Seo, Jun Suk Kim

Research output: Contribution to journalArticle

Abstract

Background: This study investigated the prognostic effects of venous thromboembolism (VTE)-related factors in patients with metastatic pancreatic cancer receiving palliative chemotherapy. Predictive factors for VTE were also investigated. Methods: A total of 216 patients diagnosed with metastatic pancreatic cancer who received gemcitabine-based palliative chemotherapy at our institution were retrospectively evaluated. Results: VTE occurred in 51 (23.6%) patients during treatment and did not affect survival. However, patients who were diagnosed with VTE at the beginning of chemotherapy showed poor prognosis compared with patients diagnosed with VTE during chemotherapy: all patients (hazard ratio [HR] 1.897, p = 0.008); patients diagnosed with VTE (HR = 3.768, p = 0.001). Low serum sodium (Na) (< 135 mmol/L) and high Khorana score (≥3) were strong predictive factors of early VTE (odds ratio [OR] 5.109; 95% confidence interval [95% CI] = 1.010-25.845; p = 0.049 for Khorana score, OR 10.304; 95% CI = 1.036-102.466; p = 0.047) for hyponatremia). Conclusions: Our study demonstrated that occurrence and detection of VTE in the early period of chemotherapy was the most significant VTE-related prognostic factor in patients with metastatic pancreatic cancer receiving chemotherapy. Prediction using the Khorana score and serum Na levels would be helpful in early diagnosis of VTE.

Original languageEnglish
Article number1260
JournalBMC Cancer
Volume18
Issue number1
DOIs
Publication statusPublished - 2018 Dec 17

Fingerprint

Venous Thromboembolism
Pancreatic Neoplasms
Retrospective Studies
Drug Therapy
gemcitabine
Odds Ratio
Confidence Intervals
Hyponatremia
Serum
Early Diagnosis
Sodium
Survival

Keywords

  • Chemotherapy
  • Hyponatremia
  • Khorana score
  • Pancreatic cancer
  • Predictive value
  • Prognosis
  • Venous thromboembolism

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Cite this

@article{16ff962e93894828bed2422eb3ee2105,
title = "Early venous thromboembolism at the beginning of palliative chemotherapy is a poor prognostic factor in patients with metastatic pancreatic cancer: A retrospective study",
abstract = "Background: This study investigated the prognostic effects of venous thromboembolism (VTE)-related factors in patients with metastatic pancreatic cancer receiving palliative chemotherapy. Predictive factors for VTE were also investigated. Methods: A total of 216 patients diagnosed with metastatic pancreatic cancer who received gemcitabine-based palliative chemotherapy at our institution were retrospectively evaluated. Results: VTE occurred in 51 (23.6{\%}) patients during treatment and did not affect survival. However, patients who were diagnosed with VTE at the beginning of chemotherapy showed poor prognosis compared with patients diagnosed with VTE during chemotherapy: all patients (hazard ratio [HR] 1.897, p = 0.008); patients diagnosed with VTE (HR = 3.768, p = 0.001). Low serum sodium (Na) (< 135 mmol/L) and high Khorana score (≥3) were strong predictive factors of early VTE (odds ratio [OR] 5.109; 95{\%} confidence interval [95{\%} CI] = 1.010-25.845; p = 0.049 for Khorana score, OR 10.304; 95{\%} CI = 1.036-102.466; p = 0.047) for hyponatremia). Conclusions: Our study demonstrated that occurrence and detection of VTE in the early period of chemotherapy was the most significant VTE-related prognostic factor in patients with metastatic pancreatic cancer receiving chemotherapy. Prediction using the Khorana score and serum Na levels would be helpful in early diagnosis of VTE.",
keywords = "Chemotherapy, Hyponatremia, Khorana score, Pancreatic cancer, Predictive value, Prognosis, Venous thromboembolism",
author = "Kim, {Jung Sun} and Kang, {Eun Joo} and Kim, {Dae Sik} and Choi, {Yoon Ji} and Lee, {Suk Young} and Kim, {Hong Jun} and Seo, {Hee Yeon} and Kim, {Jun Suk}",
year = "2018",
month = "12",
day = "17",
doi = "10.1186/s12885-018-5154-3",
language = "English",
volume = "18",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Early venous thromboembolism at the beginning of palliative chemotherapy is a poor prognostic factor in patients with metastatic pancreatic cancer

T2 - A retrospective study

AU - Kim, Jung Sun

AU - Kang, Eun Joo

AU - Kim, Dae Sik

AU - Choi, Yoon Ji

AU - Lee, Suk Young

AU - Kim, Hong Jun

AU - Seo, Hee Yeon

AU - Kim, Jun Suk

PY - 2018/12/17

Y1 - 2018/12/17

N2 - Background: This study investigated the prognostic effects of venous thromboembolism (VTE)-related factors in patients with metastatic pancreatic cancer receiving palliative chemotherapy. Predictive factors for VTE were also investigated. Methods: A total of 216 patients diagnosed with metastatic pancreatic cancer who received gemcitabine-based palliative chemotherapy at our institution were retrospectively evaluated. Results: VTE occurred in 51 (23.6%) patients during treatment and did not affect survival. However, patients who were diagnosed with VTE at the beginning of chemotherapy showed poor prognosis compared with patients diagnosed with VTE during chemotherapy: all patients (hazard ratio [HR] 1.897, p = 0.008); patients diagnosed with VTE (HR = 3.768, p = 0.001). Low serum sodium (Na) (< 135 mmol/L) and high Khorana score (≥3) were strong predictive factors of early VTE (odds ratio [OR] 5.109; 95% confidence interval [95% CI] = 1.010-25.845; p = 0.049 for Khorana score, OR 10.304; 95% CI = 1.036-102.466; p = 0.047) for hyponatremia). Conclusions: Our study demonstrated that occurrence and detection of VTE in the early period of chemotherapy was the most significant VTE-related prognostic factor in patients with metastatic pancreatic cancer receiving chemotherapy. Prediction using the Khorana score and serum Na levels would be helpful in early diagnosis of VTE.

AB - Background: This study investigated the prognostic effects of venous thromboembolism (VTE)-related factors in patients with metastatic pancreatic cancer receiving palliative chemotherapy. Predictive factors for VTE were also investigated. Methods: A total of 216 patients diagnosed with metastatic pancreatic cancer who received gemcitabine-based palliative chemotherapy at our institution were retrospectively evaluated. Results: VTE occurred in 51 (23.6%) patients during treatment and did not affect survival. However, patients who were diagnosed with VTE at the beginning of chemotherapy showed poor prognosis compared with patients diagnosed with VTE during chemotherapy: all patients (hazard ratio [HR] 1.897, p = 0.008); patients diagnosed with VTE (HR = 3.768, p = 0.001). Low serum sodium (Na) (< 135 mmol/L) and high Khorana score (≥3) were strong predictive factors of early VTE (odds ratio [OR] 5.109; 95% confidence interval [95% CI] = 1.010-25.845; p = 0.049 for Khorana score, OR 10.304; 95% CI = 1.036-102.466; p = 0.047) for hyponatremia). Conclusions: Our study demonstrated that occurrence and detection of VTE in the early period of chemotherapy was the most significant VTE-related prognostic factor in patients with metastatic pancreatic cancer receiving chemotherapy. Prediction using the Khorana score and serum Na levels would be helpful in early diagnosis of VTE.

KW - Chemotherapy

KW - Hyponatremia

KW - Khorana score

KW - Pancreatic cancer

KW - Predictive value

KW - Prognosis

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=85058638956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058638956&partnerID=8YFLogxK

U2 - 10.1186/s12885-018-5154-3

DO - 10.1186/s12885-018-5154-3

M3 - Article

C2 - 30558603

AN - SCOPUS:85058638956

VL - 18

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 1260

ER -